JP2006523091A - ヒト胚性幹細胞の心筋細胞への分化 - Google Patents
ヒト胚性幹細胞の心筋細胞への分化 Download PDFInfo
- Publication number
- JP2006523091A JP2006523091A JP2006503961A JP2006503961A JP2006523091A JP 2006523091 A JP2006523091 A JP 2006523091A JP 2006503961 A JP2006503961 A JP 2006503961A JP 2006503961 A JP2006503961 A JP 2006503961A JP 2006523091 A JP2006523091 A JP 2006523091A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- cardiomyocytes
- hes
- embryonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 197
- 230000004069 differentiation Effects 0.000 title claims abstract description 58
- 210000001671 embryonic stem cell Anatomy 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 261
- 238000000034 method Methods 0.000 claims abstract description 86
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims abstract description 9
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims abstract description 9
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 230000001605 fetal effect Effects 0.000 claims description 42
- 210000002308 embryonic cell Anatomy 0.000 claims description 40
- 210000000130 stem cell Anatomy 0.000 claims description 40
- 210000001900 endoderm Anatomy 0.000 claims description 31
- 230000009278 visceral effect Effects 0.000 claims description 24
- 108090000862 Ion Channels Proteins 0.000 claims description 21
- 102000004310 Ion Channels Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000004217 heart function Effects 0.000 claims description 19
- 238000002054 transplantation Methods 0.000 claims description 19
- 230000002861 ventricular Effects 0.000 claims description 18
- 230000000747 cardiac effect Effects 0.000 claims description 17
- 238000003501 co-culture Methods 0.000 claims description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims description 17
- 238000010009 beating Methods 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- 210000005003 heart tissue Anatomy 0.000 claims description 14
- 230000007831 electrophysiology Effects 0.000 claims description 13
- 238000002001 electrophysiology Methods 0.000 claims description 13
- 230000002107 myocardial effect Effects 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 12
- 230000018109 developmental process Effects 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 238000010186 staining Methods 0.000 claims description 12
- 208000019622 heart disease Diseases 0.000 claims description 11
- 230000001746 atrial effect Effects 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 7
- 238000003255 drug test Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 239000002327 cardiovascular agent Substances 0.000 claims description 6
- 229940125692 cardiovascular agent Drugs 0.000 claims description 6
- 239000002356 single layer Substances 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 210000003976 gap junction Anatomy 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 102000003922 Calcium Channels Human genes 0.000 claims description 4
- 108090000312 Calcium Channels Proteins 0.000 claims description 4
- 229930001406 Ryanodine Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008828 contractile function Effects 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000009067 heart development Effects 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 claims description 4
- 102000010970 Connexin Human genes 0.000 claims description 3
- 108050001175 Connexin Proteins 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 210000004457 myocytus nodalis Anatomy 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000013553 cell monolayer Substances 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 230000007045 gastrulation Effects 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 239000011575 calcium Substances 0.000 description 18
- 230000000541 pulsatile effect Effects 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 12
- 230000036982 action potential Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 6
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 102000010825 Actinin Human genes 0.000 description 5
- 108010063503 Actinin Proteins 0.000 description 5
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 5
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 210000002242 embryoid body Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002235 sarcomere Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 4
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 230000010349 pulsation Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 229960001722 verapamil Drugs 0.000 description 4
- 102000001045 Connexin 43 Human genes 0.000 description 3
- 108010069241 Connexin 43 Proteins 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 3
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 3
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 3
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 230000002057 chronotropic effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000002458 fetal heart Anatomy 0.000 description 3
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 210000001811 primitive streak Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102000013975 Delayed Rectifier Potassium Channels Human genes 0.000 description 2
- 108010050556 Delayed Rectifier Potassium Channels Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 102000005937 Tropomyosin Human genes 0.000 description 2
- 108010030743 Tropomyosin Proteins 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960001317 isoprenaline Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101710194927 Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
- 101100174722 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAA1 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002336 epiblast cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000023061 limb morphogenesis Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- -1 lucifer yellow lithium salt Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003901099A AU2003901099A0 (en) | 2003-03-11 | 2003-03-11 | Methods of inducing differentiation of stem cells |
| PCT/AU2004/000302 WO2004081205A1 (en) | 2003-03-11 | 2004-03-11 | Differentiation of human embryonic stem cells to cardiomyocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523091A true JP2006523091A (ja) | 2006-10-12 |
| JP2006523091A5 JP2006523091A5 (https=) | 2007-05-24 |
Family
ID=31500143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503961A Pending JP2006523091A (ja) | 2003-03-11 | 2004-03-11 | ヒト胚性幹細胞の心筋細胞への分化 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070161107A1 (https=) |
| EP (1) | EP1608740A4 (https=) |
| JP (1) | JP2006523091A (https=) |
| AU (1) | AU2003901099A0 (https=) |
| CA (1) | CA2518508A1 (https=) |
| GB (1) | GB2415437A (https=) |
| WO (1) | WO2004081205A1 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010047133A1 (ja) * | 2008-10-24 | 2010-04-29 | 株式会社クラレ | 細胞保存方法、及び細胞輸送方法 |
| WO2010134606A1 (ja) | 2009-05-22 | 2010-11-25 | 学校法人 東京女子医科大学 | 胚性幹細胞或いは人工多能性幹細胞の分化誘導方法 |
| JP2013531497A (ja) * | 2010-06-13 | 2013-08-08 | インスティチュート・オブ・バイオフィジックス，チャイニーズ・アカデミー・オブ・サイエンシズ | 幹細胞から心筋細胞を調製するための方法および組成物ならびにその使用 |
| JP2014525268A (ja) * | 2011-08-30 | 2014-09-29 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 心筋細胞を生成するための方法 |
| WO2015025958A1 (ja) * | 2013-08-23 | 2015-02-26 | 国立大学法人大阪大学 | ペースメーカー組織片の製造方法 |
| US11339371B2 (en) | 2012-07-23 | 2022-05-24 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro |
| WO2024162286A1 (ja) | 2023-01-31 | 2024-08-08 | 富士フイルム株式会社 | 薬剤の評価方法、試薬およびキット |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732199B2 (en) | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
| WO2003006950A2 (en) | 2001-07-12 | 2003-01-23 | Geron Corporation | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| US7452718B2 (en) | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| CA2569242A1 (en) * | 2004-06-01 | 2005-12-15 | Es Cell International Pte Ltd | Improved cardiomyocyte differentiation |
| CA2611809C (en) | 2005-06-22 | 2018-06-19 | Geron Corporation | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| WO2008073331A2 (en) * | 2006-12-07 | 2008-06-19 | Teva Pharmaceutical Industries Ltd. | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
| US20080300642A1 (en) * | 2007-05-30 | 2008-12-04 | Japan As Represented By President Of National Cardiovascular Center | Regeneration treatment apparatus, operating method thereof, and regeneration treatment method |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009036220A2 (en) * | 2007-09-12 | 2009-03-19 | The Regents Of The University Of California | Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes |
| JP5558097B2 (ja) | 2007-12-10 | 2014-07-23 | 国立大学法人京都大学 | 効率的な核初期化方法 |
| US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| CN101939418A (zh) | 2008-01-30 | 2011-01-05 | 杰龙公司 | 用于培养干细胞衍生的心肌细胞的合成表面 |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
| BRPI0922572A2 (pt) | 2008-12-17 | 2019-09-24 | Scripps Research Inst | método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero. |
| AU2010306627B2 (en) | 2009-10-16 | 2014-07-17 | The Scripps Research Institute | Induction of pluripotent cells |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2012087965A2 (en) | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
| EP2948542A4 (en) | 2013-01-23 | 2016-07-13 | Ronald Li | MANIPULATED PHYSICAL ORIENTATION OF CARDIOMYOCYTES FROM STEM CELLS |
| US10087436B2 (en) | 2014-02-06 | 2018-10-02 | The Regents Of The University Of California | Electrophysiologically mature cardiomyocytes and methods for making same |
| SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| SG10202111851YA (en) | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
| CN113662985B (zh) | 2021-09-07 | 2022-06-24 | 北京中医药大学 | 具有促进干细胞定向分化为心肌细胞作用的中药组合物、中药有效组分组合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003010303A1 (en) * | 2001-07-24 | 2003-02-06 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2493588C (en) * | 2002-07-26 | 2012-09-11 | Wisconsin Alumni Research Foundation | Functional cardiomyocytes from human embryonic stem cells |
| WO2005054448A1 (en) * | 2003-12-04 | 2005-06-16 | Guhathakurta Dr Soma | A novel process and method for deriving cardiomyocyte precursors from bone-marrow stem cells |
-
2003
- 2003-03-11 AU AU2003901099A patent/AU2003901099A0/en not_active Abandoned
-
2004
- 2004-03-11 US US10/548,501 patent/US20070161107A1/en not_active Abandoned
- 2004-03-11 WO PCT/AU2004/000302 patent/WO2004081205A1/en not_active Ceased
- 2004-03-11 EP EP04719333A patent/EP1608740A4/en not_active Withdrawn
- 2004-03-11 CA CA002518508A patent/CA2518508A1/en not_active Abandoned
- 2004-03-11 JP JP2006503961A patent/JP2006523091A/ja active Pending
- 2004-03-11 GB GB0520673A patent/GB2415437A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003010303A1 (en) * | 2001-07-24 | 2003-02-06 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010047133A1 (ja) * | 2008-10-24 | 2010-04-29 | 株式会社クラレ | 細胞保存方法、及び細胞輸送方法 |
| JPWO2010047133A1 (ja) * | 2008-10-24 | 2012-03-22 | 株式会社クラレ | 細胞保存方法、及び細胞輸送方法 |
| WO2010134606A1 (ja) | 2009-05-22 | 2010-11-25 | 学校法人 東京女子医科大学 | 胚性幹細胞或いは人工多能性幹細胞の分化誘導方法 |
| JP2013531497A (ja) * | 2010-06-13 | 2013-08-08 | インスティチュート・オブ・バイオフィジックス，チャイニーズ・アカデミー・オブ・サイエンシズ | 幹細胞から心筋細胞を調製するための方法および組成物ならびにその使用 |
| US9273286B2 (en) | 2010-06-13 | 2016-03-01 | Institute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof |
| US10590386B2 (en) | 2010-06-13 | 2020-03-17 | Insitute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof |
| JP2014525268A (ja) * | 2011-08-30 | 2014-09-29 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 心筋細胞を生成するための方法 |
| US11339371B2 (en) | 2012-07-23 | 2022-05-24 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro |
| WO2015025958A1 (ja) * | 2013-08-23 | 2015-02-26 | 国立大学法人大阪大学 | ペースメーカー組織片の製造方法 |
| WO2024162286A1 (ja) | 2023-01-31 | 2024-08-08 | 富士フイルム株式会社 | 薬剤の評価方法、試薬およびキット |
| KR20250130369A (ko) | 2023-01-31 | 2025-09-01 | 후지필름 가부시키가이샤 | 약제의 평가 방법, 시약 및 키트 |
| EP4660316A1 (en) | 2023-01-31 | 2025-12-10 | FUJIFILM Corporation | Drug evaluation method, reagent and kit |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2415437A (en) | 2005-12-28 |
| GB0520673D0 (en) | 2005-11-16 |
| WO2004081205A8 (en) | 2004-10-28 |
| WO2004081205A1 (en) | 2004-09-23 |
| CA2518508A1 (en) | 2004-09-23 |
| US20070161107A1 (en) | 2007-07-12 |
| EP1608740A4 (en) | 2007-05-09 |
| AU2003901099A0 (en) | 2003-03-27 |
| EP1608740A1 (en) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523091A (ja) | ヒト胚性幹細胞の心筋細胞への分化 | |
| US8728457B2 (en) | Methods of inducing differentiation of stem cells | |
| US9994822B2 (en) | Cardiomyocyte differentiation | |
| JP5312804B2 (ja) | 幹細胞及び胎児由来の心筋細胞及び予定心筋細胞の精製方法 | |
| AU2002317039A1 (en) | Methods of inducing differentiation of stem cells | |
| US20100183566A1 (en) | METHOD FOR EFFICIENT TRANSFER OF HUMAN BLASTOCYST-DERIVED STEM CELLS (hBS CELLS) FROM A FEEDER-SUPPORTED TO A FEEDER-FREE CULTURE SYSTEM | |
| JP2017525393A (ja) | ヒト心室前駆体細胞を単離するための細胞表面マーカーとしてのＪａｇｇｅｄ１／Ｆｒｉｚｚｌｅｄ４の使用 | |
| Wobus et al. | Embryonic stem cell-derived cardiac differentiation: modulation of differentiation and “loss-of-function” analysis in vitro | |
| JP2019535299A (ja) | ヒト心室前駆細胞を単離するための方法 | |
| WO2006066320A1 (en) | Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom | |
| AU2004219990A1 (en) | Differentiation of human embryonic stem cells to cardiomyocytes | |
| Pera | Differentiation of Human Embryonic Stem Cells to Cardiomyocytes Role of Coculture With Visceral Endoderm-Like Cells | |
| AU2005318931A1 (en) | Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom | |
| JP2008141973A (ja) | 心筋細胞の培養増殖法 | |
| Shafa et al. | Stirred Suspension Bioreactor Suppresses ESC Differentiation | |
| Hosseini | Ultrastructural comparison of developing mouse embryonic stem cell-and in vivo-derived cardiomyocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070312 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070312 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100917 |